Roche Holding AG(RHHBF)

Description: Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. Roche Holding AG has collaboration with Gilead Sciences, Inc. for COVID-19; a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza, as well as SemaThera Inc. to develop biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases; and has collaboration with Affimed N.V to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR expressing solid tumors. The company was founded in 1896 and is headquartered in Basel, Switzerland.

---

Keywords: Cancer Life Sciences Pharmaceutical Products Organic Compounds Chemical Compounds Solid Tumors Rheumatoid Arthritis Lymphoma Leukemia Transplantation Hepatitis B Anemia Diabetic Retinopathy Metabolic Disorders HIV/Aids Inflammatory In Vitro Diagnostics Retinopathy Skin Cancer Gilead Sciences Hoffmann La Roche Prescription Pharmaceuticals Respiratory Disorders Shionogi Roche Baloxavir Marboxil In Vitro Diagnostics Solutions Ischemic Retinal Diseases

---

Home Page: www.roche.com

Konzern Hauptsitz
Basel, 4070
Switzerland
Phone: 41 61 688 11 11

---

Officers

Exchange: OTCQX

Country: US

Currency: US Dollar ($)